Completed PHASE1 INTERVENTIONAL 2-arm NCT01369459

Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder (MIP)

Family-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD

Sponsor: National Institute on Drug Abuse (NIDA)

Conditions Attention Deficit Disorder Attention Deficit Hyperactivity Disorder

Updated 5 times since 2017 Last updated: Aug 3, 2015 Started: Nov 30, 2011 Primary completion: Mar 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder, this trial is completed. The trial is conducted by National Institute on Drug Abuse (NIDA) and has accumulated 5 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Drug Abuse (NIDA)
The National Center on Addiction and Substance Abuse at Columbia University

Data source: The National Center on Addiction and Substance Abuse at Columbia University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States